55
https://pubmed.ncbi.nlm.nih.gov/38117497
Sodium-glucose cotransporter 2 inhibitors are associated with a lower risk of sight-threatening retinopathy compared to DPP-4i, pioglitazone, and sulfonylureas in patients with type 2 diabetes.